You don't need to be signed in to read BMJ Blogs, but you can register here to receive updates about other BMJ products and services via our site.

Continuous infliximab treatment rather than intermittent for plaque psoriasis

11 Jun, 13 | by kuppell

Continuous therapy with infliximab is more effective than intermittent therapy and is associated with fewer side effects in patients with moderate to severe plaque-type psoriasis according to a study published in the British Journal of Dermatology.

Eligible patients for inclusion in the extension study, RESTORE2, had received infliximab for 26 weeks and achieved Psoriasis Area and Severity Index (PASI) score of 75 in the initial RESTORE1 study. Of these, 222 patients were randomised to receive continuous infliximab treatment (5mg/kg every 8 weeks) and 219 received intermittent treatment (no infliximab until >50% loss of PASI improvement). The researchers say that more serious infusion-related reactions occurred with intermittent treatment (8/219 patients, 4%) than with continuous treatment (1/222 patients, <1%) which lead to termination of the study.  Although no formal efficacy analyses were conducted, continuous therapy led to greater PASI 75 at week 52 in the continuous group (81/101, 80%) than in the intermittent group (39/83, 47%).

‘For patients with moderate-to-severe plaque-type psoriasis, continuous therapy with infliximab may be more effective than intermittent therapy. The incidence of serious infusion-related reactions in the intermittent group suggests that clinicians should avoid intermittent therapy in this population,’ advise the researchers. Br J of Dermatol 2013;168:1325-34.

By submitting your comment you agree to adhere to these terms and conditions
You can follow any responses to this entry through the RSS 2.0 feed.

Latest from European Journal of Hospital Pharmacy

Latest from European Journal of Hospital Pharmacy